Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder - PubMed (original) (raw)
Review
Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder
Carlos A Zarate et al. CNS Drugs. 2009.
Abstract
Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.
Figures
Fig. 1
Protein kinase C (PKC) in the pathophysiology and treatment of manic behaviour. DA = dopamine; GAP-43 = growth-associated protein of 43 kDa; NA = noradrenaline (norepinephrine); ↑ indicates increased.
Fig. 2
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study design and dose escalation.
Fig. 3
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study (reproduced from Zarate et al.[55]). Tamoxifen vs placebo: * p < 0.05 after correction. Week vs baseline for tamoxifen: * p < 0.05, ** p < 0.01, *** p < 0.001 after correction. YMRS = Young Mania Rating Scale.
Similar articles
- Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.
Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Yildiz A, et al. Arch Gen Psychiatry. 2008 Mar;65(3):255-63. doi: 10.1001/archgenpsychiatry.2007.43. Arch Gen Psychiatry. 2008. PMID: 18316672 Clinical Trial. - A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.
DiazGranados N, Zarate CA Jr. DiazGranados N, et al. Curr Psychiatry Rep. 2008 Dec;10(6):510-9. doi: 10.1007/s11920-008-0081-7. Curr Psychiatry Rep. 2008. PMID: 18980735 Free PMC article. Review. - [Possible involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder].
Einat H, Chen G, Manji H. Einat H, et al. Harefuah. 2004 Jun;143(6):420-5, 462. Harefuah. 2004. PMID: 15524099 Review. Hebrew. - Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder.
Hahn CG, Friedman E. Hahn CG, et al. Bipolar Disord. 1999 Dec;1(2):81-6. doi: 10.1034/j.1399-5618.1999.010204.x. Bipolar Disord. 1999. PMID: 11252663 Review. - Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania.
Abrial E, Bétourné A, Etiévant A, Lucas G, Scarna H, Lambás-Señas L, Haddjeri N. Abrial E, et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu031. doi: 10.1093/ijnp/pyu031. Int J Neuropsychopharmacol. 2014. PMID: 25577667 Free PMC article.
Cited by
- The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder.
Bagdadi N, N Azab A, Shvartsur R. Bagdadi N, et al. Psychiatry Clin Psychopharmacol. 2021 Sep 1;31(3):344-352. doi: 10.5152/pcp.2021.21817. eCollection 2021 Sep. Psychiatry Clin Psychopharmacol. 2021. PMID: 38765942 Free PMC article. - New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.
Bortolozzi A, Fico G, Berk M, Solmi M, Fornaro M, Quevedo J, Zarate CA Jr, Kessing LV, Vieta E, Carvalho AF. Bortolozzi A, et al. Pharmacol Rev. 2024 May 2;76(3):323-357. doi: 10.1124/pharmrev.120.000007. Pharmacol Rev. 2024. PMID: 38697859 Free PMC article. Review. - An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.
Machado-Vieira R, Courtes AC, Zarate CA Jr, Henter ID, Manji HK. Machado-Vieira R, et al. Front Neurosci. 2023 Aug 1;17:1228455. doi: 10.3389/fnins.2023.1228455. eCollection 2023. Front Neurosci. 2023. PMID: 37592949 Free PMC article. Review. - A critical evaluation of dynamical systems models of bipolar disorder.
Nunes A, Singh S, Allman J, Becker S, Ortiz A, Trappenberg T, Alda M. Nunes A, et al. Transl Psychiatry. 2022 Sep 28;12(1):416. doi: 10.1038/s41398-022-02194-4. Transl Psychiatry. 2022. PMID: 36171199 Free PMC article. Review.
References
- Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11 (3):227–40. - PubMed
- Manji HK, Zarate CA. Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics. Mol Psychiatry. 2002;7 (Suppl 1):S1–7. - PubMed
- Zarate CA, Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59 (11):1006–20. - PubMed
- Casabona G. Intracellular signal modulation: a pivotal role for protein kinase C. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21 (3):407–25. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical